Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a γ genotype

Diane M. Da Silva a,b,c,1, Carly A. Movius c,1, Adam B. Raff b,2, Heike E. Brand b, Joseph G. Skeate c, Michael K. Wong d, W. Martin Kast a,b,c

a Department of Obstetrics & Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
b Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
c Department of Molecular Microbiology & Immunology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
d Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA

Abstract

Human papillomavirus (HPV) has evolved mechanisms that allow it to evade the human immune system. Studies have shown HPV-mediated suppression of activation of Langerhans cells (LC) is a key mechanism through which HPV16 evades initial immune surveillance. However, it has not been established whether high- and low-risk mucosal and cutaneous HPV genotypes share a common mechanism of immune suppression. Here, we demonstrate that LC exposed to capsids of HPV types 18, 31, 45, 11, (alpha-papillomaviruses) and HPV5 (beta-papillomavirus) similarly suppress LC activation, including lack of costimulatory molecule expression, lack of cytokine and chemokine secretion, lack of migration, and deregulated cellular signaling. In contrast, HPV1 (mu-papillomavirus) induced costimulatory molecule and cytokine upregulation, but LC activation was suppressed. These results suggest that alpha and beta HPV genotypes, and partially a γ genotype, share a conserved mechanism of immune escape that enables these viruses to remain undetected in the absence of other inflammatory events.

Article Info

Article history:
Received 5 November 2013
Returned to author for revisions 27 November 2013
Accepted 31 January 2014
Available online 17 February 2014

Keywords:
Human papillomavirus
Langerhans cell
Immune suppression
Immune escape
Antigen presentation
Antigen presenting cell
Migration

Introduction

Human papillomavirus (HPV) infection is causally associated with the development of benign and malignant lesions, including various types of cancer (Walboomers et al., 1999). Over 170 genotypes of HPV have been identified to date, each with preferential tropism for particular locations (i.e. mucosal versus cutaneous) and with varying propensities for causing cancer (i.e. high-risk versus low-risk) (Lizano et al., 2009). It is estimated that 15% of women with a high-risk HPV infection are unable to mount an effective immune response (Stanley et al., 2007), and viral clearance takes on average about one year (Winer et al., 2011), indicating that HPV possesses mechanisms to escape immune detection and clearance.

The life cycle of HPV occurs within the epithelium of the skin and mucosa and is dependent on the differentiation of epithelial cells, making in vitro studies challenging. As alternatives to native virions, multiple particle platforms have been developed, such as virus-like particles (VLPs) and pseudovirions (PsV), which both generate HPV particles that contain the major capsid protein L1 and minor capsid protein L2 (Kernbauer et al., 1993; Roden et al., 1996; Zhou et al., 1991). Due to the location of HPV infection, the resident antigen presenting cells in the epithelium, Langerhans cells (LC), are the first immune cell to contact HPV and therefore are thought to be responsible for initiating an effective anti-viral immune response (Banchereau and Steinman, 1998). Upon recognition of a foreign antigen, LC undergo maturation, which consists of phenotypic and functional changes including up-regulation of MHC and co-stimulatory molecules, secretion of cytokines and chemokines, and migration to regional lymph nodes where T cell activation takes place (Cunningham et al., 2008). However, we have previously demonstrated that human LC exposed to the high-risk genotype HPV16 do not become activated, suggesting a HPV16 immune escape mechanism specifically targeting LC (Fausch et al., 2002). We furthermore demonstrated that this HPV16 immune escape mechanism was dependent on the presence of the minor capsid protein L2 (Fahey et al., 2009). HPV actively changes the LC through deregulation of the PI3 kinase (PI3K)-Akt signaling pathway such that although they present HPV peptides on their MHC molecules to T cells; this presentation occurs in the absence of T cell co-stimulatory molecules and essential T cell activating cytokines (Fausch et al., 2003, 2005a, 2005b). The resulting immunological phenotype is an LC that can potentially induce T cell tolerance and/or inhibit subsequent T cell recognition of HPV.
Whether the LC-specific immune escape mechanism exhibited by HPV16 is also utilized by other HPV genotypes, including other high-risk mucosal genotypes, low-risk mucosal genotypes and cutaneous genotypes, has been an intriguing question. Because we had previously shown that the immune escape mechanism was dependent on the HPV16 L2 minor capsid protein (Fahey et al., 2009) and the L2 protein has highly conserved regions across multiple genotypes (Lowe et al., 2008; Yang et al., 2003), we hypothesized that other HPV genotypes besides HPV16 would similarly initiate immune escape by targeting antigen presentation by LC. To explore this hypothesis, we exposed human monocyte-derived LC to high-risk mucosal genotypes associated with malignancy (HPV16, HPV18, HPV31 and HPV45), a low-risk mucosal genotype associated with benign genital condylomas (HPV11) and cutaneous genotypes associated with skin lesions (HPV5) or hand and foot warts (HPV1), and subsequently assessed the phenotypic and functional immunologic characteristics of virus exposed LC.

Results

Phenotypic activation of LC after treatment with high- and low-risk mucosal HPV genotypes and cutaneous HPV genotypes

HPV particles representative of high-risk mucosal HPV types (HPV16, HPV18, HPV31, HPV45), a low-risk mucosal HPV type (HPV11), and cutaneous HPV types (HPV1, HPV5) were generated by overexpression of the L1 and L2 genes in either insect cells for virus-like particles (VLP) or in the 293TT human embryonic kidney cell line for pseudovirions (PsV). To determine the effect of different HPV genotypes on phenotypic maturation of LC, we assessed the expression of cell surface activation markers on LC after exposure to HPV16, HPV18, HPV31, HPV45, HPV11 and HPV5, and subsequently assessed the phenotypic and functional immunologic characteristics of virus exposed LC.

Cytokine and chemokine secretion by LC after treatment with high- and low-risk HPV genotypes and cutaneous HPV genotypes

The cytokine and chemokine profile generated by activated antigen presenting cells plays an important role in directing the adaptive immune response. Therefore, to next assess functional activation of LC, we analyzed the levels of cytokines and chemokines secreted by LC after exposure to HPV16, HPV18, HPV31, HPV45, HPV11, HPV5 and HPV1. Secretion of IL-6, TNFα, MIP-1α and RANTES after exposure to all tested HPV genotypes, except for HPV1, was similar to untreated LC (Fig. 2). Consistent with the upregulation of activation markers observed above, LC stimulated with HPV1 demonstrated a significant

---

**Fig. 1.** High and low risk mucosal HPV genotypes and a cutaneous HPV genotype all suppress phenotypic activation of LC in contrast to HPV1. Human immature LC were left untreated, treated with LPS (positive control) or exposed to various HPV genotypes for 48 h at 37 C. Subsequently, cells were analyzed by flow cytometry for expression of MHC molecules, costimulatory markers, and maturation markers. Analysis was performed on total population of large cells (>75% of total population) which are 95% CD1a+ (indicative of LC phenotype). Shown are MHC class II, CD80, CD86, and CD83 markers. High-risk mucosal HPV genotypes treated on LC include HPV16, HPV18, HPV31, and HPV45. HPV11 is the representative low-risk HPV genotype. HPV5 and HPV1 are the representative cutaneous HPV genotypes. Fold change of surface marker expression was calculated based on mean fluorescence intensity (MFI) normalized against the untreated LC. Data is a representation of mean ± SD of LC from 8 healthy donors. (*p < 0.05, **p < 0.01).
increase in the secretion of MIP-1b and RANTES (p < 0.05), and a moderate increase in IL-6 and TNFα, indicative of a pro-inflammatory immune response. For the majority of secreted immune mediators analyzed, LC exposed to the HPV particles maintained baseline secretion of pro-inflammatory cytokines and chemokines analyzed (Table S1), supporting the view that, in general, LC remain in an immature state after HPV encounter, particularly with non-cutaneous genotypes.

Migration of LC in response to exposure with high- and low-risk HPV genotypes and cutaneous HPV genotype

Once activated, antigen presenting cells migrate to draining lymph nodes using the cell surface receptor CCR7, which binds to the lymph node associated chemokine CCL21 (Saeki et al., 1999). By utilizing a transwell migration assay with CCL21, we assessed the migratory capacity of LC after exposure to HPV16, HPV18, HPV31, HPV45, HPV11, HPV5 and HPV1. While exposure to LPS caused the LC to increase their migration towards CCL21, LC exposed to all of the HPV types, including HPV1, maintained a steady state migration similar to untreated LC (Fig. 3), suggesting that exposure to viral particles does not induce migration of local LC to lymphocyte-rich areas where immune reactions take place.

Deregulation in the Akt signaling pathway in LC after treatment with high- and low-risk mucosal HPV genotypes and cutaneous HPV genotypes

In our previous studies we demonstrated that the mechanism of HPV16-induced immune escape in LC occurred through the deregulation of the PI3K–Akt pathway, as shown by a decrease in phospho-Akt (p-Akt, Ser 473) (Fausch et al., 2005a, 2005b). To determine if this signaling pathway plays a role in immune escape of other HPV genotypes, LC were exposed to HPV16, HPV18, HPV31, HPV45, HPV11, HPV5 and HPV1 and subsequently assayed for the levels of p-Akt and total Akt. LC exposed to all HPV genotypes tested demonstrated a decrease in p-Akt compared to baseline p-Akt levels in untreated LC at 15 min and 30 min post-exposure (Fig. 4A), indicating they share a common mechanism for suppressing LC signaling. The relative p-Akt concentration was

Fig. 2. Cytokine and chemokine secretion by LC are similar after treatment with high and low risk HPV genotypes and cutaneous HPV5, in contrast to HPV1. Supernatant from LC were collected after 48 h of treatment with LC only, LPS, high-risk (HPV16, HPV18 VLPs and HPV31, HPV45 PsV), low-risk (HPV11 VLP) or cutaneous genotypes (HPV5 PsV, HPV1 VLP). Cell supernatants were analyzed for a panel of 12 cytokines and chemokines (IL-1β, IFNα, IL-6, IL-8, IL-10, IL-12 p70, TNFα, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES) using a Bio-plex suspension bead ELISA (BioRad, Hercules, CA). Shown are four analytes selected from the panel of 12. Data represent the mean(±SEM) analyte concentration of 4 individual healthy donors tested. (⁎p < 0.05, **p < 0.01).

Fig. 3. Migration of LC does not change in response to exposure with high- and low-risk mucosal and cutaneous HPV genotypes. Human LC were treated with LPS or HPV genotypes indicated for 48 h and then were analyzed for migration through a 5 μm transwell insert to medium alone or medium supplemented with 250 ng/mL CCL21/SLC. After 4 h, cells migrating to the lower chamber containing chemokine were counted. Visualization of migrating cells by microscopy showed only large “LC-like” cells moving through the transwell membrane. Shown is the mean migration index calculated as the number of cells migrating to CCL21 over spontaneous migration (∼SEM) of 6 healthy donors relative to untreated LC. No significant differences are observed between the untreated LC and LC exposed to different HPV genotypes. (**p < 0.01).
quantified and normalized to GAPDH and confirms the decrease in p-Akt compared to untreated LC (Fig. 4B). The largest decreases in p-Akt were observed after 15 min, whereas by 30 min levels of p-Akt were returning to, but still below baseline. These results suggest that diverse HPV genotypes are able to cause a down regulation of signal transduction molecules in LC that normally control the transcription of immune response genes and cell survival and point to a potential mechanism for inhibiting the function of LC in the epidermal tissue during HPV infection.

Discussion

LC, also known as epidermal dendritic cells (DC), only constitute 3–5% of nucleated cells in the epidermis, but are able to form an expansive cellular network through their extended dendrites that survey the epidermis for foreign antigens (Romani et al., 2003). Classically, activated LC are thought to migrate to the lymph nodes, present antigen and activate antigen-specific T-cells. However, recent studies have challenged the importance of LC in the initiation of skin immunity (Romani et al., 2012). Studies in mice have identified a specialized subset of langerin+ CD103+ dermal DC which cross-present antigen to CD8+ T cells when the antigen is exclusively expressed in keratinocytes (Bedoui et al., 2009; Henri et al., 2010). Furthermore, long-term effector/memory CD4+ T cells are induced only when dermal DC are present, although LC presenting epidermally expressed antigen can still stimulate CD4+ T cell proliferation (Shklovskaya et al., 2011). Selective depletion of langerin+ LC in mice results in enhanced contact hypersensitivity to haptens, suggesting that in the steady-state, when LC are present, epidermal immune responses are suppressed (Bobr et al., 2010; Kaplan et al., 2005). Human studies have shown, however, that LC isolated from human skin can cross-present antigen, prime naïve CD8+ T cells and preferentially expand antigen-specific cytotoxic T lymphocytes (CTLs) (Klechevsky et al., 2008). Notably, mouse skin and human skin differ quite substantially both anatomically and immunologically, and it is unclear whether a human equivalent exists to mouse langerin+ CD103+ dermal DC. Investigation of APC subsets in human skin from cutaneous HPV genotypes reveals that skin APCs have distinct phenotypes and specialized functions in directing local immune responses which are different from other tissues and organs, including skin and gut (Duluc et al., 2013). LC isolated from human vaginal tissue have been shown to induce naïve CD8+ T cell proliferation and are able to induce CD8+ T cells expressing the cytokines IFNγ and TNFα. Overall, it is clear that human LC can contribute both to immune suppression as well as immune activation, the outcome being determined by the particular environment, the presence or absence of inflammation and the presence of pathogenic stimuli.

HPV infections may take many months to years to be cleared (Ho et al., 1998; Winer et al., 2011), even for non-oncogenic strains (Giuliano et al., 2002), suggesting that HPVls have acquired the ability to either remain hidden or suppress the immune system. Persistence of an HPV infection is the greatest risk factor in the development of HPV-related malignancies (Schlecht et al., 2001). Previously, we identified an HPV16 capsid-driven immune escape mechanism that suppresses the immunostimulatory function of LC (Fausch et al., 2003, 2002, 2005a, 2005b). When HPV16, a high risk mucosal HPV genotype, comes into contact with LC, the result is that HPV16 actively prevents LC maturation into an activated antigen presenting cell (APC). The current study indicates that other HPV genotypes besides HPV16, such as high-risk (HPV18, HPV31, and HPV45), low-risk (HPV11) and a cutaneous (HPV5) genotype, also suppress LC activation through a similar mechanism. By inhibiting the maturation of the APC at the site of infection, these representative HPV genotypes prevent the induction of the HPV-specific adaptive immune response required for viral clearance. Human LC have been shown to internalize papillomavirus capsids from diverse genotypes, including animal papillomaviruses (Fausch et al., 2005a; Yan et al., 2004), suggesting that differential HPV antigen uptake is unlikely to be responsible for the effects we observed in this study. Notably, APC displaying peptides in the absence of both costimulation and pro-inflammatory cytokines have the ability to cause T cell anergy (Frauwirth et al.,

Fig. 4. Disruption in the Akt signaling pathway in LC is similar after treatment with high- and low-risk mucosal HPV genotypes and cutaneous HPV genotypes. (A) Cellular extracts from LC exposed to HPV genotypes for 15 min (top) or 30 min (bottom) at 37°C were separated by SDS-PAGE, transferred to PVDF and immunoblotted using antibodies to p-Akt (Ser473), total Akt, and GAPDH. Visualization was performed using the Odyssey Infrared Imaging System. (B) Protein bands were quantified using the Odyssey system software, normalized to total Akt and GAPDH expression, and the relative levels of pAkt (mean ± SEM) compared to untreated LC are shown from three individual experiments.
2000) and generate regulatory T cells (Dhodapkar and Steinman, 2002; Dhodapkar et al., 2001), the latter being increased in HPV-associated pre-neoplastic lesions and in cervical cancer compared to healthy tissue (Leong et al., 2010b; Scott et al., 2009; van der Burg et al., 2007).

To date, 170 genotypes of HPV have been sequenced and are clustered based on the major L1 capsid, the type of infection caused (whether mucosal or cutaneous), and their ability to either induce cancer or benign condylomas (Bernard, 2005; De Villiers, 2013). From the alpha-papillomavirus genus, HPV16 and HPV18 are most frequently associated with cervical cancer. Importantly, the four high risk genotypes analyzed in this study – HPV16, HPV18, HPV31, and HPV45 – are the most prevalent genotypes attributed to causing greater than 75% of all cervical squamous cell carcinoma (Smith et al., 2007). Low risk HPV genotypes from the alpha-papillomavirus group are associated with benign condylomas with the highest occurrence of genital warts primarily associated with HPV6 and laryngeal papillomas primarily associated with HPV11. Cutaneous mu-papillomavirus genotypes such as HPV1 are generally benign and associated with foot and hand warts. However, some cutaneous beta-papillomavirus genotypes such as HPV5 and HPV8 have been associated with epidermodysplasia verruciformis, a cutaneous neoplastic disease, and can also be associated with skin cancer in immune compromised individuals (Bernard, 2005).

Although papillomaviruses are distinct enough to be classified into different genera and have distinct life-cycle characteristics and disease associations, one characteristic is fairly consistent – which is the majority, if not all, of HPVs tend to persist longer than the typical transient viral infection. Longitudinal natural history studies demonstrate that infection with high-risk oncopapillomavirus types persist on average for greater than one year. The median duration of cervical infection in young women has been reported to be anywhere from 12–19 months for HPV16 and HPV31, and 9–15 months for HPV18 and HPV45 (Ho et al., 1998; Kulmala et al., 2007; Moscicki et al., 2004; Richardson et al., 2003). Low-risk types such as HPV6 and HPV11 persist on average for six months (Ho et al., 1998; Richardson et al., 2003). The ability of the high-risk types (HPV16, 18, 31, 45) to persist longer than a low risk type (HPV11) despite them being equally capable of inducing LC dysfunction may be related to other virally mediated mechanisms contributing to immune escape such as differential modulation of keratinocyte gene expression, and antiviral and inflammatory cytokines (Kanodia et al., 2007). Similar to the mucosatropic alpha-papillomaviruses, our data suggest that even cutaneous HPV genotypes (HPV5 and partially HPV1) can suppress LC immune function. Clinical observations indicate that cutaneous warts in healthy individuals generally regress within 3–6 months with regression being accompanied by dense mononuclear cell infiltrates (Jablonska et al., 1997). However, asymptomatic subclinical infection with cutaneous HPV types is very prevalent and some studies indicate cutaneous HPVs, such as HPV5, can persist for months to years (De Koning et al., 2007, 2009; Hazard et al., 2007). It is interesting to note that LC exposed to HPV16 secreted increased levels of MIP-1b and RANTES (Fig. 2), two chemokines that are chemoattractant towards CD4+ T cells, B cells, DC, monocytes and polymorphonuclear cells. If LC become activated when HPV16-producing lesions become sufficiently large to provide enough virion stimulation to LC, secretion of these chemokines may be sufficient to cause mononuclear cell infiltration to biologically promote wart regression.

Related to the potential functional impact on LC suppression by the HPV capsid proteins of diverse genotypes that we observe, it has also been shown by Leong et al. that LC numbers and E-cadherin expression in HPV infected tissue are reduced in lesions infected with alpha-, gamma- and mu-papillomaviruses, but not the beta-papillomavirus types indicating that other effects on LC dysfunction are conserved across diverse HPV genera (Leong et al., 2010a, 2010b). Moreover, keratinocytes infected with high-risk HPV16 can block the differentiation of monocytes into LC in a contact dependent manner (Iijima et al., 2013). These observations, together with our data, suggest that a consequence of early HPV infection by a majority of genotypes from diverse genera is to dampen the immune response via suppression of LC that are initially present in the epidermis of healthy tissue. Following infection of keratinocytes, HPV gene expression results in further host immune suppression by causing a reduction in the LC adjacent to infected cells, promoting immune evasion and favoring viral persistence (Kanodia et al., 2007).

In our study, a significant amount of capsid was required to observe partial LC activation by HPV1. When we titrated the HPV1 capsids and decreased the capsid:LC ratio, we did observe that the upregulation of surface markers was decreased. This observation suggests that low HPV1 infectious doses would be even less likely to trigger an antiviral immune reaction, also contributing to preventing immune recognition despite the fact that some cutaneous lesions and warts can become sizable and produce large amounts of infectious particles. In natural infections, it is not known how many viral particles are required to alert epithelial LC to the presence of viral pathogen. However, a significant observation is that some cutaneous HPV infections result in epithelial tissue which is less cornified, leading to more fragile cell envelopes that can easily be broken, releasing high concentrations of virions that can encounter surrounding LC in the infected individual (Brown and Bryan, 2000). During person to person transmission, virions can be delivered in concentrated packages by desquamated cornified cells, releasing a focal amount of virions on a small area of epithelium (Bryan and Brown, 2001), which would enhance the likelihood of LC of the uninfected person coming into contact with a concentrated amount of virions.

Our study reveals that, in general, diverse genotypes (mucosal, cutaneous, high-risk, and low-risk) tend to interact with human LC similarly to cause immune suppression. This finding may allude to the utilization of similar cell surface receptors on LCs and epithelial cells, though productive infection is not expected to take place in myeloid-derived immune cells. Early events of papillomavirus infection are believed to use shared mechanisms based on studies demonstrating similar infection susceptibility of mucosal and skin tissues with diverse HPV genotypes (Handisurya et al., 2012). Additionally, efficiency of infection, based on reporter gene transcription, was the same for human and animal papillomavirus types, suggesting that downstream post-cell entry events determine papillomavirus species and tissue tropism rather than initial capsid interactions and virus entry (Handisurya et al., 2012). It is therefore surprising that in our study certain properties of LC were different when exposed to the HPV1 cutaneous genotype. Although LC migration and Akt signaling were not demonstrably affected, high dose HPV1-exposed LC did become partially activated through upregulation of surface molecules and secretion of cytokines involved in adaptive immunity, suggesting that, at least for HPV1, the host response is more reactive to this papillomavirus genotype compared to the other genotypes that were used at the same capsid concentration. Whether these partially activated LC are able to induce HPV1-specific T cells in vivo cannot be determined from our study.

As described earlier, the LC-specific immune escape mechanism of HPV16 was shown to be dependent on the presence of the L2 protein, because capsids composed solely of the HPV16 L1 major capsid protein are capable of activating LC, whereas HPV16 capsids containing L2 do not (Tahey et al., 2009). Capsids composed solely of the HPV6b L1 protein have also been shown to activate LC (Yan et al., 2004). The L2 protein has several conserved regions in its amino acid sequence across genotypes such as L2(13–31) and...
L2 (108–120) which have previously been implicated in cell surface entry and binding events, respectively (Kawana et al., 2001; Lowe et al., 2008; Yang et al., 2003). Therefore, suppression of LC across diverse genotypes may be due to the conserved nature of the L2 protein sequence. Recently, our laboratory has demonstrated that the HPV16 L2 (108–120) region binds to the S100A10 subunit of the annexin A2 heterotetramer (A2t) on epithelial cells (Woodham et al., 2012). Further, the interaction between HPV16 L2 and A2t was shown to contribute to HPV16 internalization and infection, particularly the L2 (108–111) region (Woodham et al., 2012). Importantly, all of the particles used in this study contained the L2 protein of each genotype (Fig. S3), resulting in use of capsids identical to physiologically relevant wild-type capsids. Whether this conserved L2 region of all genotypes mediates the demonstrated immune escape mechanism, through binding to A2t on LC, is an active area of research in our group. Supporting this idea, we have found that HPV16 capsids are taken up by LC and functionally suppress LC maturation through an interaction with A2t in an L2-dependent manner (Woodham et al., submitted for publication).

Notably, the L2 proteins from HPV1 and HPV5 contain an extra 34 and 45 amino acids, respectively, compared to HPV16 L2, whereas the L2 proteins from HPV18, 31 and 45 show more sequence conservation to HPV16. Interestingly, when key amino acids in the L2 (108–111) region are aligned, the HPV1 L2 sequence is the most different from HPV16 and the consensus sequence of the region between the papillomavirus genotypes tested in this study (Fig. 5). This observation suggests that amino acid divergence in this key A2t-binding region may be responsible for differential immunological outcomes post interaction with LC surface receptors. Additional studies will be needed to explore whether sequence differences in the L2 protein between different HPV genotypes affect their ability to initiate LC immune suppression.

Papillomavirus capsid binding to the cell surface is associated with epithelial cell signaling, even before the majority of virus is internalized. One study showed that several high risk HPV genotypes and bovine papillomavirus induce tyrosine kinase and PI3K signaling events resulting in downstream signaling to Akt, which the authors proposed was a result of virus binding to integrins (Fothergill and McMillan, 2006). In contrast, whereas in epithelial cells the PI3K pathway is activated, we have previously shown that HPV16 disconnects PI3K signaling from downstream Akt signaling (Fausch et al., 2005a). The observation that all of the HPV genotypes tested here appear to suppress Akt signaling in LC extend these findings to other HPV genotypes, pointing to a common mechanism of immune evasion through deregulated cellular signaling.

While this study evaluated a variety of HPV genotypes from representative classes, we have not ruled out that genotypes not tested here may behave differently. HPV5s have evolved a variety of mechanisms for immune escape and likely utilize a combination of approaches to subvert the immune system and maintain persistent infections. However, this study suggests a conserved mechanism of immune escape through targeting LC amongst high-risk, low-risk and at least one cutaneous HPV genotype, and furthers our understanding of the interaction between divergent HPV types and the human immune system.

Materials and methods

Generation of human Langerhans cells

Human Langerhans cells (LC) were derived as described previously and express phenotypic markers characteristic of skin-derived LC (Langerin+, E-cadherin+, CD11c+, CD1a+) (Fig. S1) (Fausch et al., 2002; Geissmann et al., 1998). These studies were approved by the University of Southern California Institutional Review Board and informed consent was obtained from all donors.

HPV pseudovirions and virus-like particles

HPV1, HPV11, HPV16, and HPV18 VLP were produced using a recombinant baculovirus expression system in Trichoplusia ni (Hi-5) insect cells as previously described and purified using sucrose cushion and cesium chloride density gradient ultracentrifugation (Fausch et al., 2002; Kirnbauer et al., 1992). HPV5, HPV16, HPV18, HPV31, and HPV45 pseudovirions were generated in 293TT cells and purified by optiprep (iodixanol) density gradient ultracentrifugation as described previously using the adapted protocol for bulk replication-incompetent PsV production (Buck and Thompson, 2007). Plasmid constructs (p5sheLL, p16sheLL, p18sheLL, p31sheLL, p45sheLL) were kindly provided by Dr. John Schiller (National Cancer Institute). Capsids were subjected to SDS-PAGE and Western blot analyses to confirm the presence of L1 and L2 proteins (Fig. S3), while transmission electron microscopy confirmed the presence of intact particles. Coomasie Blue staining following SDS-PAGE was performed to determine viral stock purity and standardize the concentration of L1 content of the VLP and PsV preparations. Capsid preparations were negative for endotoxin contamination as tested with an E-toxate (Limulus amebocyte lysate (LAL) assay kit (Sigma-Aldrich), or 5 µg HPV VLP or PsV/106 cells. LC were incubated for 1 h at 37 °C, mixed occasionally, then incubated at 37 °C for an additional 48 h at a cell concentration of 1 × 105 cells/mL. Supernatants were collected for cytokine analysis and cells were harvested, washed, stained for surface markers or isotype controls. The following human antibodies were purchased from BD Biosciences (San Jose, CA): HLA-DP/DQ/DR-FITC, CD40-PE, CD86-FITC, CD1a-PE, CD197 (CCR7), mouse IgG1-PE, goat anti-rat IgG-PE, goat anti-mouse IgG1-FITC, rat IgG2a isotype control, mouse IgG1-FITC, mouse IgG1-PE, mouse IgG2b-FITC. The following human antibodies were purchased from Biologend (San Diego, CA): HLA-ABC-FITC, CD80-FITC, CD83-PE, CD207-PE (Langerin), CD324-PE (E-cadherin), Human TruStain FcX (Fc receptor blocking solution). Samples were analyzed by flow cytometry on a Cytomics FC500 flow cytometer using CXP software (Beckman Coulter, Indianapolis, IN).

LC activation

Immature LC were either left untreated, treated with 5 µg LPS (Sigma-Aldrich), or 5 µg HPV VLP or PsV/106 cells. LC were incubated for 1 h at 37 °C, mixed occasionally, then incubated at 37 °C for an additional 48 h at a cell concentration of 1 × 105 cells/mL. Supernatants were collected for cytokine analysis and cells were harvested, washed, stained for surface markers or isotype controls. The following human antibodies were purchased from BD Biosciences (San Jose, CA): HLA-DP/DQ/DR-FITC, CD40-PE, CD86-FITC, CD1a-PE, CD197 (CCR7), goat anti-rat IgG-PE, goat anti-mouse IgG1-FITC, rat IgG2a isotype control, mouse IgG1-FITC, mouse IgG1-PE, mouse IgG2b-FITC. The following human antibodies were purchased from Biologend (San Diego, CA): HLA-ABC-FITC, CD80-FITC, CD83-PE, CD207-PE (Langerin), CD324-PE (E-cadherin), Human TruStain FcX (Fc receptor blocking solution). Samples were analyzed by flow cytometry on a Cytomics FC500 flow cytometer using CXP software (Beckman Coulter, Indianapolis, IN).
Secreted cytokines and chemokines were analyzed using the Bio-Plex Suspension Array System (Bio-Rad, Hercules, CA) using a Milliplex MAP human cytokine/chemokine kit containing detection reagents for interferon (IFN)α, interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70, Inducible Protein 10 (IP-10), tumor necrosis factor (TNF)α, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES (EMD Millipore, Billerica, MA).

Migration assay

Chemokine directed migration of LC was carried out using 24-well Transwell plates with 5 μm-pore-size polycarbonate filters (Corning Costar, Tewksbury, MA). Media was added to the lower chamber containing either 250 ng/ml recombinant human CCL21 (R&D Systems, Minneapolis, MN) or medium alone to control for spontaneous migration. LC untreated or treated as described in the LC activation assay were added to the upper chamber and incubated for 4 h at 37 °C. The cells that migrated to the lower chamber were harvested and counted using a 21 Beckman Coulter particle counter. CCL21-dependent migration was calculated as the ratio of cells that migrated with CCL21 to cells that migrated spontaneously, termed migration index.

Immunoblotting

LC were treated as described in the activation assay at 37 °C for 15 min. Cellular extracts were prepared using the Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL). Equal concentrations of cell lysates were electrophoresed on 10% NuPage Novex Bis–Tris gels (Life Technologies) and transferred to PVDF membranes. Immunoblotting was performed using p-Akt, Akt and GAPDH antibodies (Cell Signaling Technologies, Danvers, MA) and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Statistical analysis

All statistical analyses were performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA).

Acknowledgments

We thank John Schiller and Chris Buck for providing pseudo-virion plasmids for the HPV genotypes used in this study. We thank Neil Christensen, John Schiller, and Robert Garcia for providing L1 and L2 antibodies used in immunoblots. This research was supported by Public Health Service Grant R01 CA074397 from the National Cancer Institute (to W.M.K.). The project described was supported in part by Award number P30CA140498 from the National Cancer Institute (to Norris Comprehensive Cancer Center). Contributions from the Netherlands American Foundation and the Karl H. and Ruth M. Balz Trust are also gratefully acknowledged. W. Martin Kast holds the Walter A. Richter Cancer Research Chair. Cytokine multiplex assays were run with the assistance of the USC Norris Comprehensive Cancer Center Beckman Center for Immune Monitoring. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Appendix. Supporting information

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.virol.2014.01.031.

References


